Cited by 121Cancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersChromatin Remodeling and Cancer

The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters

Open access
Levine, Arnold J., Jenkins, Nancy A., Copeland, Neal G.·2019·Cancer Cell

Abstract

We propose that initiating truncal mutations plays a special role in tumor formation by both enhancing the survival of the initiating cancer cell and by selecting for secondary mutations that contribute to tumor progression, and that these mutations often act in a tissue-preferred fashion. Here, we explain why inherited mutations often have different tissue specificities compared with spontaneous mutations in the same gene. Initiating truncal mutations make excellent neo-antigens for immunotherapy, and understanding why one mutation selects for a second mutation in a particular tissue type could one day aid in the design of gene-targeted combination therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2018.11.009

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The tissue of origin and developmental context determine whether potentially transforming mutations lead to cancer initiation.

    “The tissue of origin and developmental context also determine whether potentially transforming mutations result in cancer initiation (6).”

    From Metabolic reprogramming and cancer progression (2020) · cites this paper as [6]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 32 · Cited by 121

Authors
Levine, A. J., Jenkins, N. A., & Copeland, N. G.
Affiliations
  • Institute for Advanced Study (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Levine, Arnold J.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2019-01
Volume
35
Issue
1
Pages
10-15
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2909020461
Cited by
121
References
32
Citations by year
2026: 20 · 2025: 9 · 2024: 16 · 2023: 19 · 2022: 12 · 2021: 22 · 2020: 16 · 2019: 7
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
NCI (5 P01CA087497 -17)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
tumor progression, secondary mutations, tissue specificity, inherited mutations, spontaneous mutation, neoantigens, cancer immunotherapy, tumor cell survival
MeSH terms
Animals, Humans, Immunotherapy, Mutation, Neoplasms, Organ Specificity, Drug Design, Disease Progression, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review